If you have been reading about quality control and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
α-1-Adrenoceptor, an adrenergic receptor with the primary effect of vasoconstriction Alpha-1 blocker, a variety of drugs which block α1-adrenergic receptors in arteries and smooth muscles Adenosine A1 receptor EPH receptor A1 A1, a subfamily of rhodopsin-like receptors SR-A1, a type of scavenger receptors domains
Molecular analysis of CPOX is the best way to identify these patients, as they will not express a biochemical phenotype on laboratory testing unless they are symptomatic. Identification of asymptomatic patients allows them to adjust their lifestyle to avoid common triggering factors.
=== Exercise === Horses with PSSM show fewer clinical signs if their exercise is slowly increased over time (i.e. they are slowly conditioned). Additionally, they are much more likely to develop muscle stiffness and rhabdomyolysis if they are exercised after prolonged stall rest. Horses generally have fewer clinical signs when asked to perform short bouts of work at maximal activity level (anaerobic exercise), although they have difficulty achieving maximal speed and tire faster than unaffected horses. They have more muscle damage when asked to perform lower intensity activity over a longer period of time (aerobic activity), due to an energy deficit in the muscle.
1993/1250) Aviation Security (Jersey) Order 1993 (S.I. 1993/1251) Financial Provisions (Northern Ireland) Order 1993 (S.I. 1993/1252) Serbia and Montenegro (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1253) Serbia and Montenegro (United Nations Sanctions) (Isle of Man) Order 1993 (S.I. 1993/1254) Maximum Number of Judges (No. 2) Order 1993 (S.I. 1993/1255) Arbitration (Foreign Awards) Order 1993 (S.I. 1993/1256) Designs (Convention Countries) Order 1993 (S.I. 1993/1257) Patents and Marks (Convention and Relevant Countries) Order 1993 S.I. 1993/1258) Hackney and Tower Hamlets (London Borough Boundaries) Order 1993 (S.I. 1993/1260) Bromley and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1261) Kensington and Chelsea and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1262) Food Premises (Registration) (Welsh Form of Application) Regulations 1993 (S.I. 1993/1270) Greenwich and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1276) Ealing, Hillingdon and Hounslow (London Borough Boundaries) Order 1993 (S.I. 1993/1277) Treatment of Spruce Bark Order 1993 (S.I. 1993/1282) Plant Health (Forestry) (Great Britain) Order 1993 (S.I. 1993/1283) Prohibition of the Keeping or the Release of Live Fish (Pikeperch) (Scotland) Order 1993 (S.I. 1993/1288) A27 Trunk Road (Patching Junction Improvement) Order 1993 (S.I. 1993/1293) A27 Trunk Road (Patching Junction Improvement Slip Roads) Order 1993 (S.I. 1993/1294) A27 Trunk Road (Patching Junction Improvement) (Detrunking) Order 1993 (S.I. 1993/1295)
Sources: en.wikipedia.org
=== Police corruption accusation === In 2007, a representative of Innocence en Danger, a global NGO launched in 1999 to combat pedophilia, at the time with international offices in Germany, France and the United States, said that "the corrupt police [of Portugal] don't care" about the problem, and cited as an example the cases of Mendonça and Madeleine McCann. After three years, the NGO gave up trying to open an office in Portugal, saying that they were pressured by local authorities.
=== 2007 === Davey made his AFL debut in the opening round of the 2007 season, making an immediate impression and played in every game until Round 14. He has featured several times amongst the Bombers' best including an outstanding ANZAC Day match. In his first five AFL matches he earned five “goal of the year” nominations including two on ANZAC Day. Davey became known for his explosive speed. He has been known to take 2.75 secs to run from 0–20 metres. This is thought to be the fastest in the league, even more than speedster Chris Judd. From debut, Davey became one of the shortest players in the AFL. He quickly earned a cult following at Essendon, gaining the nickname is "Froggy", due to his appearance. During the round 14 game against Geelong, he suffered a broken arm when crashed into while on the ground by Kane Tenace. The injury forced Davey to miss the rest of the season, and Essendon's form slumped during the period that he was on the sidelines, eventually missing the finals. At the end of the 2007 AFL season, Alwyn won the AFL Army Award, recognising players who produce act(s) of bravery or selflessness to promote the cause of his team, during a game for his smother and 2nd and 3rd efforts against Hawthorn in round 6. He had 3 of the final 6 nominations in the award.
== Medical uses == Synthetic cannabinoids can provide psychotropic effects such as relieving nausea and dizziness. Phenethylamine can relieve depressive symptoms while Alprazolam can treat insomnia, panic attack and anxiety. The most common delivery routes of Alprazolam and Phenethylamine are by oral administration. Both of which are available in the dosage forms of pills and tablets. Synthetic cannabinoids are naturally in solid and oil form and are delivered by smoking.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.